Nitric oxide delivery to cancer: Why and how?

European Journal of Cancer

Volumn 45, Issue 8, 2009, Pages 1352-1369

  Sonveaux, Pierre ^a   Jordan, Bénédicte F ^a   Gallez, Bernard ^a   Feron, Olivier ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Blood flow; Cell respiration; Chemotherapy; Drug delivery; Imaging; Nitric oxide; Radiotherapy; Tumour oxygenation; Tumour vasculature; Vasodilation

Indexed keywords

GLYCERYL TRINITRATE; INSULIN; ISOSORBIDE DINITRATE; LINSIDOMINE; MOLSIDOMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; RADIOSENSITIZING AGENT; VASODILATOR AGENT;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL RESPIRATION; COLON CARCINOMA; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; ELECTROSTIMULATION; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; KIDNEY CARCINOMA; MEDICAL SOCIETY; MONITORING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY;

ANIMALS; CELL HYPOXIA; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; OXYGEN; PERFUSION; RADIATION-SENSITIZING AGENTS; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 65049091113     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.12.018     Document Type: Article

References (193)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Roots R., and Smith K.C. On the nature of the oxygen effect on X-ray-induced DNA single-strand breaks in mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med 26 5 (1974) 467-480
3. Horsman M.R., and Overgaard J. The oxygen effect and tumour microenvironment. In: Steel G.G. (Ed). Basic clinical radiobiology (2002), Hodder Arnold Publication, London 156-168
4. Braun R.D., Lanzen J.L., Snyder S.A., and Dewhirst M.W. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am J Physiol Heart Circ Physiol 280 6 (2001) H2533-H2544
5. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 285 21 (1971) 1182-1186
6. Kerbel R.S. Tumor angiogenesis. New Engl J Med 358 19 (2008) 2039-2049
7. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 6801 (2000) 249-257
8. Tong R.T., Boucher Y., Kozin S.V., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 11 (2004) 3731-3736
9. Ansiaux R., Baudelet C., Jordan B.F., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 2 Pt 1 (2005) 743-750
10. Zhou Q., Guo P., and Gallo J.M. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 14 5 (2008) 1540-1549
11. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 9 (2001) 987-989
12. Algire G.H., Chalkely H.W., Legallais F.Y., and Park H. Vascular reactions of normal and malignant tumors in vivo: I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6 (1945) 73-85
13. Gullino P.M., and Grantham F.H. Studies on the exchange of fluids between host and tumor. III. Regulation of blood flow in hepatomas and other rat tumors. J Natl Cancer Inst 28 (1962) 211-229
14. Peterson H.I. Modification of tumour blood flow - a review. Int J Radiat Biol 60 1-2 (1991) 201-210
15. Tozer G.M., Prise V.E., Bell K.M., et al. Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer 74 12 (1996) 1955-1960
16. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49 23 (1989) 6449-6465
17. Dworkin M.J., Carnochan P., and Allen-Mersh T.G. Nitric oxide inhibition sustains vasopressin-induced vasoconstriction. Br J Cancer 71 5 (1995) 942-944
18. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res 48 10 (1988) 2641-2658
19. Endrich B., Intaglietta M., Reinhold H.S., and Gross J.F. Hemodynamic characteristics in microcirculatory blood channels during early tumor growth. Cancer Res 39 1 (1979) 17-23
20. Song C.W. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44 10 Suppl (1984) 4721s-4730s
21. Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol 86 3 (2008) 300-313
22. Bouzin C., and Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat 10 3 (2007) 109-120
23. Sonveaux P., Dessy C., Brouet A., et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J 16 14 (2002) 1979-1981
24. Sonveaux P., Dessy C., Martinive P., et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 64 9 (2004) 3209-3214
25. Hu J., Discher D.J., Bishopric N.H., and Webster K.A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 245 3 (1998) 894-899
26. Bagnato A., and Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 14 1 (2003) 44-50
27. Martinive P., De Wever J., Bouzin C., et al. Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 5 6 (2006) 1620-1627
28. Sonveaux P., Frerart F., Bouzin C., et al. Irradiation promotes Akt-targeting therapeutic gene delivery to the tumor vasculature. Int J Radiat Oncol Biol Phys 67 4 (2007) 1155-1162
29. Kavanagh B.D., Coffey B.E., Needham D., Hochmuth R.M., and Dewhirst M.W. The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment. Br J Cancer 67 4 (1993) 734-741
30. Dewhirst M.W., Kimura H., Rehmus S.W., et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 27 (1996) S247-S251
31. Kimura H., Braun R.D., Ong E.T., et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56 23 (1996) 5522-5528
32. Milosevic M.F., Fyles A.W., and Hill R.P. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 43 5 (1999) 1111-1123
33. Rojas A. Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 20 Suppl 1 (1991) 65-70
34. Kaanders J.H., Bussink J., and van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3 12 (2002) 728-737
35. Fukumura D., and Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74 2-3 (2007) 72-84
36. Gallez B., Jordan B.F., Baudelet C., and Misson P.D. Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn Reson Med 42 4 (1999) 627-630
37. Elfering S.L., Sarkela T.M., and Giulivi C. Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem 277 41 (2002) 38079-38086
38. Feron O., Belhassen L., Kobzik L., et al. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271 37 (1996) 22810-22814
39. Kone B.C., Kuncewicz T., Zhang W., and Yu Z.Y. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 285 2 (2003) F178-F190
40. Dreyer J., Schleicher M., Tappe A., et al. Nitric oxide synthase (NOS)-interacting protein interacts with neuronal NOS and regulates its distribution and activity. J Neurosci 24 46 (2004) 10454-10465
41. Alderton W.K., Cooper C.E., and Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J 357 Pt 3 (2001) 593-615
42. Cho H.J., Xie Q.W., Calaycay J., et al. Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 176 2 (1992) 599-604
43. Busse R., and Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 265 1-2 (1990) 133-136
44. Bredt D.S., and Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87 2 (1990) 682-685
45. Salerno J.C., Harris D.E., Irizarry K., et al. An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase. J Biol Chem 272 47 (1997) 29769-29777
46. Kuncewicz T., Balakrishnan P., Snuggs M.B., and Kone B.C. Specific association of nitric oxide synthase-2 with Rac isoforms in activated murine macrophages. Am J Physiol Renal Physiol 281 2 (2001) F326-F336
47. Lechner M., Lirk P., and Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 15 4 (2005) 277-289
48. Lala P.K., and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2 3 (2001) 149-156
49. Fukumura D., Kashiwagi S., and Jain R.K. The role of nitric oxide in tumour progression. Nat Rev Cancer 6 7 (2006) 521-534
50. Walker G., Pfeilschifter J., and Kunz D. Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone. Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation. J Biol Chem 272 26 (1997) 16679-16687
51. Kolodziejski P.J., Musial A., Koo J.S., and Eissa N.T. Ubiquitination of inducible nitric oxide synthase is required for its degradation. Proc Natl Acad Sci USA 99 19 (2002) 12315-12320
52. 2+-calmodulin and caveolin. J Biol Chem 272 25 (1997) 15583-15586
53. Fleming I., Fisslthaler B., Dimmeler S., Kemp B.E., and Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88 11 (2001) E68-E75
54. Kupatt C., Dessy C., Hinkel R., et al. Heat shock protein 90 transfection reduces ischemia-reperfusion-induced myocardial dysfunction via reciprocal endothelial NO synthase serine 1177 phosphorylation and threonine 495 dephosphorylation. Arterioscler Thromb Vasc Biol 24 8 (2004) 1435-1441
55. Feron O., Saldana F., Michel J.B., and Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 273 6 (1998) 3125-3128
56. Michel J.B., Feron O., Sase K., Prabhakar P., and Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 272 41 (1997) 25907-25912
57. Arnold W.P., Mittal C.K., Katsuki S., and Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74 8 (1977) 3203-3207
58. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem 276 35 (2001) 32663-32669
59. Brouet A., Sonveaux P., Dessy C., et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89 10 (2001) 866-873
60. Fleming I., and Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284 1 (2003) R1-R12
61. Chen Z.P., Mitchelhill K.I., Michell B.J., et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443 3 (1999) 285-289
62. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95 16 (1998) 9220-9225
63. Mayer B., Pfeiffer S., Schrammel A., et al. A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J Biol Chem 273 6 (1998) 3264-3270
64. Sonveaux P., Lobysheva I.I., Feron O., and McMahon T.J. Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda) 22 (2007) 97-112
65. Venema V.J., Ju H., Zou R., and Venema R.C. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J Biol Chem 272 45 (1997) 28187-28190
66. 2+/calmodulin binding. Biochem J 355 Pt 2 (2001) 357-360
67. Rameau G.A., Tukey D.S., Garcin-Hosfield E.D., et al. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci 27 13 (2007) 3445-3455
68. Finocchietto P., Barreyro F., Holod S., et al. Control of muscle mitochondria by insulin entails activation of Akt2-mtNOS pathway: implications for the metabolic syndrome. PLoS ONE 3 3 (2008) e1749
69. Haynes V., Elfering S., Traaseth N., and Giulivi C. Mitochondrial nitric-oxide synthase: enzyme expression, characterization, and regulation. J Bioenerg Biomembr 36 4 (2004) 341-346
70. Eberhard A., Kahlert S., Goede V., et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60 5 (2000) 1388-1393
71. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 6 (2003) 401-410
72. Lubbe A.S., and Huhnt W. Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin. Int J Microcirc Clin Exp 14 4 (1994) 218-225
73. Huhnt W., and Lubbe A.S. Venules and arterioles in xenotransplanted human colon adenocarcinoma critically constrict with hyperthermia and serotonin. J Cancer Res Clin Oncol 121 5 (1995) 267-274
74. Julien C., Payen J.F., Tropres I., et al. Assessment of vascular reactivity in rat brain glioma by measuring regional blood volume during graded hypoxic hypoxia. Br J Cancer 91 2 (2004) 374-380
75. Kashiwagi S., Izumi Y., Gohongi T., et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 115 7 (2005) 1816-1827
76. Baudelet C., Cron G.O., Ansiaux R., et al. The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed 19 1 (2006) 69-76
77. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 25 10 (2004) 536-542
78. Song C.W. Modification of blood flow. In: Molls M., and Vaupel P. (Eds). Blood perfusion and microenvironment of human tumors (1998), Springer-Verlag, Berlin 193-208
79. Zlotecki R.A., Baxter L.T., Boucher Y., and Jain R.K. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res 50 3 (1995) 429-443
80. Brown G.C., and Cooper C.E. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 356 2-3 (1994) 295-298
81. Carreras M.C., and Poderoso J.J. Mitochondrial nitric oxide in the signaling of cell integrated responses. Am J Physiol Cell Physiol 292 5 (2007) C1569-C1580
82. Poderoso J.J., Lisdero C., Schopfer F., et al. The regulation of mitochondrial oxygen uptake by redox reactions involving nitric oxide and ubiquinol. J Biol Chem 274 53 (1999) 37709-37716
83. Jordan B.F., Misson P., Demeure R., et al. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 48 2 (2000) 565-570
84. Jordan B.F., Gregoire V., Demeure R.J., et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 62 12 (2002) 3555-35561
85. Mitchell J.B., Wink D.A., DeGraff W., et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53 24 (1993) 5845-5848
86. Griffin R.J., Makepeace C.M., Hur W.J., and Song C.W. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys 36 2 (1996) 377-383
87. Howard-Flanders P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 180 4596 (1957) 1191-1192
88. Jordan B.F., Sonveaux P., Feron O., et al. Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer 109 5 (2004) 768-773
89. Janssens M.Y., Verovski V.N., Van den Berge D.L., Monsaert C., and Storme G.A. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br J Cancer 79 7-8 (1999) 1085-1089
90. De Ridder M., Verellen D., Verovski V., and Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric oxide 19 2 (2008) 164-169
91. McCarthy H.O., Coulter J.A., Robson T., and Hirst D.G. Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J Pharm Pharmacol 60 8 (2008) 999-1017
92. Bronte V., and Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5 8 (2005) 641-654
93. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4 1 (2004) 71-78
94. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., and Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65 8 (2005) 3437-3446
95. De Santo C., Serafini P., Marigo I., et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 102 11 (2005) 4185-4190
96. Bronte V., Serafini P., Mazzoni A., Segal D.M., and Zanovello P. l-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24 6 (2003) 302-306
97. Bronte V., Kasic T., Gri G., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201 8 (2005) 1257-1268
98. Bouzin C., Brouet A., De Vriese J., DeWever J., and Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 178 3 (2007) 1505-1511
99. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 9 (1996) 4604-4613
100. Calvani M., Rapisarda A., Uranchimeg B., Shoemaker R.H., and Melillo G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107 7 (2006) 2705-2712
101. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9 6 (2003) 677-684
102. Berra E., Benizri E., Ginouves A., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22 16 (2003) 4082-4090
103. Masson N., Willam C., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20 18 (2001) 5197-5206
104. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 5556 (2002) 858-861
105. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15 20 (2001) 2675-2686
106. Brune B., and Zhou J. Nitric oxide and superoxide: interference with hypoxic signaling. Cardiovasc Res 75 2 (2007) 275-282
107. Metzen E., Zhou J., Jelkmann W., Fandrey J., and Brune B. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol Biol Cell 14 8 (2003) 3470-3481
108. Quintero M., Brennan P.A., Thomas G.J., and Moncada S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. Cancer Res 66 2 (2006) 770-774
109. Kohl R., Zhou J., and Brune B. Reactive oxygen species attenuate nitric-oxide-mediated hypoxia-inducible factor-1alpha stabilization. Free Radic Biol Med 40 8 (2006) 1430-1442
110. Taylor C.T. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 409 1 (2008) 19-26
111. Sandau K.B., Fandrey J., and Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 97 4 (2001) 1009-1015
112. Li F., Sonveaux P., Rabbani Z.N., et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26 1 (2007) 63-74
113. Park Y.K., Ahn D.R., Oh M., et al. Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1alpha by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation. Mol Pharmacol 74 1 (2008) 236-245
114. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22 4 (2001) 201-207
115. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101 11 (1998) 2567-2578
116. Fukumura D., Gohongi T., Kadambi A., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98 5 (2001) 2604-2609
117. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99 11 (1997) 2625-2634
118. Gratton J.P., Lin M.I., Yu J., et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4 1 (2003) 31-39
119. Chen J.X., Lawrence M.L., Cunningham G., Christman B.W., and Meyrick B. HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium. J Appl Physiol 96 2 (2004) 612-620
120. Fukumura D., Yuan F., Endo M., and Jain R.K. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 150 2 (1997) 713-725
121. Sonveaux P., and Feron O. Nitric oxide and tumor biology. In: Lamas S., and Cadenas E. (Eds). Nitric oxide, cell signaling, and gene expression (2005), CRC Press, Boca Raton 393-418
122. Lam C.F., Sviri S., Ilett K.F., and van Heerden P.V. Inhaled diazeniumdiolates (NONOates) as selective pulmonary vasodilators. Expert Opin Investig Drugs 11 7 (2002) 897-909
123. Shan S.Q., Rosner G.L., Braun R.D., et al. Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 76 4 (1997) 429-437
124. Wood P.J., Sansom J.M., Stratford I.J., et al. Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1. Br J Cancer Suppl 27 (1996) S177-S180
125. Sonveaux P., Kaz A.M., Snyder S.A., et al. Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide. Circ Res 96 10 (2005) 1119-1126
126. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84 24 (1987) 9265-9269
127. Palmer R.M., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 6122 (1987) 524-526
128. Moya M.P., Gow A.J., McMahon T.J., et al. S-nitrosothiol repletion by an inhaled gas regulates pulmonary function. Proc Natl Acad Sci USA 98 10 (2001) 5792-5797
129. Moya M.P., Gow A.J., Califf R.M., Goldberg R.N., and Stamler J.S. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet 360 9327 (2002) 141-143
130. McMahon T.J., Ahearn G.S., Moya M.P., et al. A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension. Proc Natl Acad Sci USA 102 41 (2005) 14801-14806
131. Ignarro L.J., Fukuto J.M., Griscavage J.M., Rogers N.E., and Byrns R.E. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from l-arginine. Proc Natl Acad Sci USA 90 17 (1993) 8103-8107
132. Gladwin M.T., Schechter A.N., Kim-Shapiro D.B., et al. The emerging biology of the nitrite anion. Nat Chem Biol 1 6 (2005) 308-314
133. Millar T.M., Stevens C.R., Benjamin N., et al. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 427 2 (1998) 225-228
134. Angelo M., Singel D.J., and Stamler J.S. An S-nitrosothiol (SNO) synthase function of hemoglobin that utilizes nitrite as a substrate. Proc Natl Acad Sci USA 103 22 (2006) 8366-8371
135. Vanin A.F., Bevers L.M., Slama-Schwok A., and van Faassen E.E. Nitric oxide synthase reduces nitrite to NO under anoxia. Cell Mol Life Sci 64 1 (2007) 96-103
136. Crawford J.H., Isbell T.S., Huang Z., et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 107 2 (2006) 566-574
137. Frerart F., Sonveaux P., Rath G., et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizing strategy. Clin Cancer Res 14 9 (2008) 2768-2774
138. Holland M.A., and Kozlowski L.M. Clinical features and management of cyanide poisoning. Clin Pharm 5 9 (1986) 737-741
139. Dewhirst M.W., Ong E.T., Braun R.D., et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 79 11-12 (1999) 1717-1722
140. Martinive P., Defresne F., Bouzin C., et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66 24 (2006) 11736-11744
141. Sonveaux P., Vegran F., Schroeder T., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118 12 (2008) 3930-3942
142. Warburg O. The metabolism of tumors (1930), Constable, London p. 327
143. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 9538 (2006) 843-854
144. Crokart N., Jordan B.F., Baudelet C., et al. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys 63 3 (2005) 901-910
145. Sonveaux P., Brouet A., Havaux X., et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63 5 (2003) 1012-1019
146. Kallman R.F. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105 1 (1972) 135-142
147. Dorie M.J., and Kallman R.F. Reoxygenation in the RIF-1 tumor. Int J Radiat Oncol Biol Phys 10 5 (1984) 687-693
148. Weissfloch L., Auberger T., Feldmann H.J., et al. Oxygen tension in isotransplanted mammary carcinomas and osteosarcomas before and after irradiation. Adv Exp Med Biol 388 (1996) 495-504
149. Mason R.P., Hunjan S., Le D., et al. Regional tumor oxygen tension: fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics. Int J Radiat Oncol Biol Phys 42 4 (1998) 747-750
150. Znati C.A., Rosenstein M., Boucher Y., et al. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 56 5 (1996) 964-968
151. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 14 (1999) 3374-3378
152. Gupta V.K., Jaskowiak N.T., Beckett M.A., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8 1 (2002) 47-54
153. Zeng G., and Quon M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98 4 (1996) 894-898
154. Montagnani M., Chen H., Barr V.A., and Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 276 32 (2001) 30392-30398
155. Takahashi S., and Mendelsohn M.E. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem 278 33 (2003) 30821-30827
156. Federici M., Pandolfi A., De Filippis E.A., et al. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 109 3 (2004) 399-405
157. Kuboki K., Jiang Z.Y., Takahara N., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101 6 (2000) 676-681
158. Zeng G., Nystrom F.H., Ravichandran L.V., et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101 13 (2000) 1539-1545
159. Reid M.B. Role of nitric oxide in skeletal muscle: synthesis, distribution and functional importance. Acta Physiol Scand 162 3 (1998) 401-409
160. Jordan B.F., Beghein N., Crokart N., et al. Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiother Oncol 81 1 (2006) 112-117
161. Kingwell B.A. Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J 14 12 (2000) 1685-1696
162. Jordan B.F., Sonveaux P., Feron O., et al. Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses. Int J Radiat Oncol Biol Phys 55 4 (2003) 1066-1073
163. Ng Q.S., Goh V., Milner J., et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8 2 (2007) 111-118
164. Pluta R.M., Dejam A., Grimes G., Gladwin M.T., and Oldfield E.H. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA 293 12 (2005) 1477-1484
165. Berliner L.J., and Fujii H. In vivo spin trapping of nitric oxide. Antioxid Redox Signal 6 3 (2004) 649-656
166. Charlier N., Preat V., and Gallez B. Evaluation of lipid-based carrier systems and inclusion complexes of diethyldithiocarbamate-iron to trap nitric oxide in biological systems. Magn Reson Med 55 1 (2006) 215-218
167. Yoshimura T., Yokoyama H., Fujii S., et al. In vivo EPR detection and imaging of endogenous nitric oxide in lipopolysaccharide-treated mice. Nat Biotechnol 14 8 (1996) 992-994
168. Fujii H., Wan X., Zhong J., Berliner L.J., and Yoshikawa K. In vivo imaging of spin-trapped nitric oxide in rats with septic shock: MRI spin trapping. Magn Reson Med 42 2 (1999) 235-239
169. 2 tension measurements. Cancer Res 51 12 (1991) 3316-3322
170. Vordermark D., and Brown J.M. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?. Strahlenther Onkol 179 12 (2003) 801-811
171. Hoogsteen I.J., Marres H.A., Bussink J., van der Kogel A.J., and Kaanders J.H. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 29 6 (2007) 591-604
172. Joseph P., Jaiswal A.K., Stobbe C.C., and Chapman J.D. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys 29 2 (1994) 351-355
173. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 10 (2006) 699-757
174. Chapman J.D., Coia L.R., Stobbe C.C., et al. Prediction of tumour hypoxia and radioresistance with nuclear medicine markers. Br J Cancer Suppl 27 (1996) S204-S208
175. Mahy P., De Bast M., Gallez B., et al. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol 67 1 (2003) 53-61
176. Matsumoto K., Szajek L., Krishna M.C., et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 30 4 (2007) 873-881
177. Collins D.J., and Padhani A.R. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23 5 (2004) 65-83
178. Howe F.A., Robinson S.P., McIntyre D.J., Stubbs M., and Griffiths J.R. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14 7-8 (2001) 497-506
179. Baudelet C., and Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors?. Magn Reson Med 48 6 (2002) 980-986
180. Jordan B.F., Crokart N., Baudelet C., et al. Complex relationship between changes in oxygenation status and changes in R*2: the case of insulin and NS-398, two inhibitors of oxygen consumption. Magn Reson Med 56 3 (2006) 637-643
181. Abramovitch R., Dafni H., Smouha E., Benjamin L.E., and Neeman M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59 19 (1999) 5012-5016
182. Gross D.J., Reibstein I., Weiss L., et al. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. Clin Cancer Res 5 11 (1999) 3669-3675
183. Baudelet C., Cron G.O., Ansiaux R., et al. The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed 19 1 (2006) 69-76
184. Hunjan S., Zhao D., Constantinescu A., et al. Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. Int J Radiat Oncol Biol Phys 49 4 (2001) 1097-1108
185. Robinson S.P., and Griffiths J.R. Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philos Trans R Soc Lond B Biol Sci 359 1446 (2004) 987-996
186. Gallez B., and Swartz H.M. In vivo EPR: when, how and why?. NMR Biomed 17 5 (2004) 223-225
187. Gallez B., Baudelet C., and Jordan B.F. Assessment of tumor oxygenation by electron paramagnetic resonance. principles and applications. NMR Biomed 17 5 (2004) 240-262
188. Gallez B., and Mader K. Accurate and sensitive measurements of pO(2) in vivo using low frequency EPR spectroscopy: how to confer biocompatibility to the oxygen sensors. Free Radic Biol Med 29 11 (2000) 1078-1084
189. Charlier N., Beghein N., and Gallez B. Development and evaluation of biocompatible inks for the local measurement of oxygen using in vivo EPR. NMR Biomed 17 5 (2004) 303-310
190. Dinguizli M., Jeumont S., Beghein N., et al. Development and evaluation of biocompatible films of polytetrafluoroethylene polymers holding lithium phthalocyanine crystals for their use in EPR oximetry. Biosens Bioelectron 21 7 (2006) 1015-1022
191. Salikhov I., Walczak T., Lesniewski P., et al. EPR spectrometer for clinical applications. Magn Reson Med 54 5 (2005) 1317-1320
192. Swartz H.M., Khan N., Buckey J., et al. Clinical applications of EPR: overview and perspectives. NMR Biomed 17 5 (2004) 335-351
193. Khan N., Williams B.B., Hou H., Li H., and Swartz H.M. Repetitive tissue pO2 measurements by electron paramagnetic resonance oximetry: current status and future potential for experimental and clinical studies. Antioxid Redox Signal 9 8 (2007) 1169-1182